BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Genetown

  Parthenon Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of PRTH-101, a Novel DDR1 Inhibitor for the Treatment of Immune-Excluded Solid Tumors

  Parthenon Therapeutics today announced that the first patient has been dosed with PRTH-101 in a Phase 1, first-in-human clinical trial for patients with immune-excluded solid tumors.

  April 25, 2023

   · 

  3 min read
• Business

  Elucid Names Scott Huennekens Executive Chairman of the Board

  Elucid, Inc today announced that it has named Scott Huennekens executive chairman of its board of directors.

  April 25, 2023

   · 

  3 min read
• Business

  SOPHiA GENETICS to Announce Financial Results for the First Quarter of Fiscal 2023 on May 9, 2023

  SOPHiA GENETICS today announced it will release its financial results for the first quarter of fiscal 2023 before U.S. markets open on Tuesday, May 9, 2023.

  April 25, 2023

   · 

  1 min read
• Lone Star Bio

  Orthofix Expands Solutions for Minimally Invasive Spine Procedures with the Full Commercial Launch of Two Access Retractor Systems

  Orthofix Medical Inc today announced the full commercial launch of two access retractor systems to aid surgeons during minimally invasive spine (MIS) procedures.

  April 25, 2023

   · 

  5 min read
• Business

  Bausch + Lomb Announces 2023 Annual Meeting of Shareholder Results

  Bausch + Lomb Corporation today announced the election of the 10 directors nominated at its 2023 annual meeting of shareholders (the “Annual Meeting”) held on April 24, 2023.

  April 25, 2023

   · 

  2 min read
• Drug Development

  Atsena Therapeutics Announces Positive 6-month Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)

  Atsena Therapeutics today announced positive 6-month safety and efficacy data from the ongoing Phase I/II clinical trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1).

  April 25, 2023

   · 

  3 min read
• Bio NC

  Life Edit Therapeutics to Present Data Demonstrating Therapeutic Potential of its Novel Gene Editing Platform

  -Life Edit Therapeutics Inc. today announced the presentation of the first preclinical data from the company’s Huntington’s disease program across three presentations at CHDI’s 18th Annual Huntington’s Disease Therapeutics Conference taking place April 24-27, 2023, in Dubrovnik, Croatia.

  April 25, 2023

   · 

  6 min read
• Business

  Agenus to Provide Corporate Update and First Quarter 2023 Financial Report

  Agenus today announced the Company will release its first quarter 2023 financial results before the market opens on Tuesday, May 9, 2023.

  April 25, 2023

   · 

  3 min read
• Drug Development

  Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect

  Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM ™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect.

  April 25, 2023

   · 

  7 min read
• Biotech Beach

  Aurora Spine to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & 1x1 Meetings on Thursday, April 27, 2023

  Aurora Spine Corporation today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 at 3:00 PM (Local Time -PST).

  April 25, 2023

   · 

  2 min read